Yes - Jon says that the trofinetide success was "just the start"....
And he is much more upbeat about NNZ-2591 - he initiated the captial raising last year in the off chance that the phase 3 trofinetide trials failed. In hindsight - that was not necessary.
This is the statement that encourages me the most about Neuren...from Jon Pilcher himself...
Yes trofinetide and NNZ-2591 both originate from Dame Margaret Brimble's work in Auckland. They are analogs of two different molecules - glycine proline glutamate (GPE) and cyclic glycine proline (cGP) respectively. Each plays a role in the metabolism of IGF-1 in the brain. The desired outcome of using the power of IGF-1 in the brain is the same, but with a different mechanism to achieve it. They also have different properties as drugs, with 2591 clearly superior in a few ways.
GLTAH - 2022 with our 2 drugs this is going 2 be our year!
NEU Price at posting:
$3.77 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)